Sarker S, Spigelman A, Walker M, Coleman D
Cytopathology Unit, St Mary's Hospital Medical School, Imperial College of Science, Technology and Medicine, University of London, UK.
Anal Cell Pathol. 1997;13(1):1-8. doi: 10.1155/1997/461402.
Patients with aggressive breast cancers benefit from chemotherapy prior to surgery. If the biology of the breast cancers were better characterised pre-operatively, more patients at risk could be offered chemotherapy. We have assessed nuclear DNA content of fine needle aspirates (FNA) of 103 invasive ductal breast cancers and compared this to tumour size, node status and histological grade. Median follow-up was 18 months so no prognostic studies were made. Diploid and non-diploid tumours were distributed equally in node negative and positive patients. However non-diploidy status increased in line with known prognostic markers of tumour size and histological grade. This suggests that ploidy might contribute to the pre-operative assessment of prognosis. We conclude that nuclear DNA of breast cancer FNAs may be of value in the pre-operative biological assessment of breast cancer patients.
侵袭性乳腺癌患者在手术前接受化疗会受益。如果能在术前更好地对乳腺癌的生物学特性进行表征，那么更多有风险的患者就可以接受化疗。我们评估了103例浸润性导管乳腺癌细针穿刺抽吸物（FNA）的核DNA含量，并将其与肿瘤大小、淋巴结状态和组织学分级进行了比较。中位随访时间为18个月，因此未进行预后研究。二倍体和非二倍体肿瘤在淋巴结阴性和阳性患者中分布均等。然而，非二倍体状态随肿瘤大小和组织学分级等已知预后标志物的升高而增加。这表明倍性可能有助于术前预后评估。我们得出结论，乳腺癌FNA的核DNA可能在乳腺癌患者的术前生物学评估中具有价值。
